Weekly update Companies AI-cruiter Recruiting

Verve Therapeutics

Founded: 2019

Location: Cambridge, MA

Employee range: 50 - 200

Clinical stage: Clin1

Therapy area: Heterozygous familial hypercholesterolemia

Drug types: CVV, GEN, HEP

Lead product: VERVE-101

Product link: https://www.vervetx.com/our-programs/our-pipeline

Funding: $307M IPO Jun 2021; $94M B Jan 2021; $63M A2 Jun 2020; $58.5M A May 2019

vervetx.com

linkedin.com

job board

Short description:

Gene-editing Treatments

Drug notes:

VERVE-201 Clin0 familial hypercholesterolemia; 3 add'l products RD atherosclerotic cardiovascular disease/liver disease

Long description:

Verve Therapeutics is developing novel gene editing therapies for the treatment of cardiovascular diseases. The company has a proprietary platform for the development of base editors, which are enzymes that can make precise changes to DNA without causing harmful off-target edits. Base editors are a new class of gene editing tools that have the potential to revolutionize the treatment of genetic diseases. Unlike traditional gene editing tools, such as CRISPR/Cas9, base editors can make precise changes to a single nucleotide in DNA without causing harmful off-target edits. This makes base editors a safer and more effective tool for gene editing. Verve Therapeutics is using its proprietary base editor platform to develop therapies for a variety of cardiovascular diseases, including hypercholesterolemia and sickle cell disease.

Jobs:

Main

Contact: recruit@workinbiotech.com